Kolexia
El Yamani Abderrazak Hématologie
El Yamani Abderrazak
Hématologie
Centre Hospitalier de Blois
Blois, France
70 Activités
57 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome T Lymphome intraoculaire Tumeurs du système nerveux central Tumeurs de la rétine Récidive tumorale locale Lymphome à cellules du manteau Leucémies Myélome multiple

Collaborateurs

Voir plus
Dony Arthur
Dony Arthur
Hôpital Chambéry, Chambéry, France
Benboubker Lotfi
Benboubker Lotfi
Centre hospitalier de Tours, Tours, France
Drebit Yuriy
Drebit Yuriy
Centre Hospitalier de Beziers, Béziers, France
Lefrere Francois
Lefrere Francois
Hôpital Necker Enfants Malades, Paris, France

Industries

Voir plus
IQVIA
167 collaboration(s)
Dernière en 2023
A+A
136 collaboration(s)
Dernière en 2023
P\S\L Group Services
130 collaboration(s)
Dernière en 2023
B3TSI
82 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.
Haematologica   01 janvier 2023
Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study
Annual Meeting Abstracts 2022   15 novembre 2022
iLOC: Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   06 avril 2022
Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab
Blood   23 novembre 2021
MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA (MEITL): CLINICO-PATHOLOGICAL ANALYSIS OF A MULTICENTER EUROPEAN COHORT
16th International Conference on Malignant Lymphoma, Virtual Edition, 18–22 June, 2021   17 juin 2021
044 | MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA (MEITL): CLINICO-PATHOLOGICAL ANALYSIS OF A MULTICENTER EUROPEAN COHORT
16th International Conference on Malignant Lymphoma, Virtual Edition, 18–22 June, 2021   09 juin 2021
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
European journal of cancer (Oxford, England : 1990)   03 juillet 2019
IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE ILOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK.
14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 – 17 June, 2017   07 juin 2017
Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network
Blood   01 janvier 2016
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Annals of oncology : official journal of the European Society for Medical Oncology   19 octobre 2011